Cargando…

Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder

Apixaban is an oral small‐molecule, direct factor Xa (FXa) inhibitor approved in adults for treatment of deep vein thrombosis and pulmonary embolism, and for reducing risk of venous thromboembolism recurrence after initial anticoagulant therapy. This phase I study (NCT01707394) evaluated the pharmac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Merali, Samira J., Byon, Wonkyung, Patel, Yogesh T., Elsrougy, Amira, Marchisin, David, Perera, Vidya, Chen, Weidong, He, Bing, Murthy, Bindu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088081/ https://www.ncbi.nlm.nih.gov/pubmed/36861188 http://dx.doi.org/10.1002/psp4.12935

Ejemplares similares

The Effects of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Volunteers: A Single-Sequence Crossover Study
por: Garonzik, Samira, et al.
Publicado: (2019)

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
por: Byon, Wonkyung, et al.
Publicado: (2019)

Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure–Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism
por: Byon, W, et al.
Publicado: (2017)

Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data
por: Jamieson, Michael J., et al.
Publicado: (2022)

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
por: Frost, Charles E., et al.
Publicado: (2021)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
por: Cui, Yimin, et al.
Publicado: (2013)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
por: Frost, Charles, et al.
Publicado: (2018)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013)

Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY
por: Cohen, Alexander T., et al.
Publicado: (2021)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
Publicado: (2014)

Correction to: Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY
por: Cohen, Alexander T., et al.
Publicado: (2021)

Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants
por: Perera, Vidya, et al.
Publicado: (2022)

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban
por: Frost, Charles E., et al.
Publicado: (2015)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost, Charles, et al.
Publicado: (2014)

Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects
por: Jing, Shan, et al.
Publicado: (2023)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration
por: Serpa, Priscila B. S., et al.
Publicado: (2018)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Phase I study of single‐dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients
por: Moudgil, Asha, et al.
Publicado: (2019)

Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects
por: Wang, Xiaoli, et al.
Publicado: (2013)

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
por: Frost, Charles, et al.
Publicado: (2017)

Influence of Surface-Modification via PEGylation or Chitosanization of Lipidic Nanocarriers on In Vivo Pharmacokinetic/Pharmacodynamic Profiles of Apixaban
por: Zaky, Mohamed F., et al.
Publicado: (2023)

Real-World Analysis of Potential Pharmacokinetic and Pharmacodynamic Drug Interactions with Apixaban in Patients with Non-Valvular Atrial Fibrillation
por: Badreldin, Hisham A, et al.
Publicado: (2020)

Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti‐CD28 Domain Antibody Antagonist in Healthy Subjects
por: Shi, Rong, et al.
Publicado: (2016)

Transferability of Published Population Pharmacokinetic Models for Apixaban and Rivaroxaban to Subjects with Obesity Treated for Venous Thromboembolism: A Systematic Review and External Evaluations
por: Leven, Cyril, et al.
Publicado: (2023)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
por: Yang, Haijing, et al.
Publicado: (2022)

Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
por: Hu, Yingying, et al.
Publicado: (2023)

Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects
por: Togawa, Michinori, et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism
por: Harder, Sebastian
Publicado: (2014)

Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects
por: Chimalakonda, Anjaneya, et al.
Publicado: (2022)

The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects
por: Stavros, Fiona, et al.
Publicado: (2010)

Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects
por: Dolder, Patrick C., et al.
Publicado: (2017)

Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects
por: Hasunuma, Tomoko, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
por: Li, Yinhua, et al.
Publicado: (2021)

Population pharmacokinetics and exposure–response analyses of varenicline in adolescent smokers
por: Fediuk, Daryl J., et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function
por: Teng, Renli, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qrbis6dl4qehhpdf30aescr8vf